Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Amplify Transformational Data Sharing ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Amplify Transformational Data Sharing ETF trades at $60.92. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | BLOK | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $74.10 |
52-Week Low | $20.06 | $47.36 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BLOK trades at $63.47, up 3.07% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces resistance at $64 and support at $62. Recent news highlights the ETF's exposure to AI infrastructure and Bitcoin mining stocks, though analyst sentiment has turned cautious due to increased crypto market correlation.
The outlook remains neutral with technical indicators divided and fundamental data limited. Key risks include reliance on volatile crypto markets and competitive ETF pressures. Analyst consensus suggests holding pending clearer catalysts from AI infrastructure growth or Bitcoin market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
